Antidepressant and antiparkinsonian compounds
    2.
    发明公开
    Antidepressant and antiparkinsonian compounds 失效
    Antidepressiv und gegen die Parkinsonsche Krankheit wirkende Verbindungen。

    公开(公告)号:EP0604354A2

    公开(公告)日:1994-06-29

    申请号:EP93610065.0

    申请日:1993-12-20

    申请人: NEUROSEARCH A/S

    IPC分类号: C07D451/02 A61K31/46

    CPC分类号: C07D451/00

    摘要: The present invention discloses compounds of the formula

    any mixture thereof, or a pharmaceutically acceptable salt thereof ;
    wherein R, R 3 , and R 4 each have the meanings set forth in the specification.
    The compounds possess valuable pharmaceutical properties as dopamine reuptake inhibitors.

    摘要翻译: 本发明公开了式CHEM的任何混合物或其药学上可接受的盐; 其中R,R 3和R 4各自具有说明书中阐述的含义。 该化合物具有有价值的药物性质作为多巴胺再摄取抑制剂。

    Novel isatineoxime derivatives, their preparation and use
    6.
    发明公开
    Novel isatineoxime derivatives, their preparation and use 失效
    Neue Isatineoxime Derivate,ihre Herstellung und Verwendung。

    公开(公告)号:EP0522494A1

    公开(公告)日:1993-01-13

    申请号:EP92111478.1

    申请日:1992-07-07

    申请人: NEUROSEARCH A/S

    IPC分类号: C07D209/60 A61K31/40

    CPC分类号: C07D209/60

    摘要: A compound having the formula

    wherein
    R¹ is C₁₋₆-alkyl which may be branched or cyclic;
    R² is C₁₋₆-alkyl which may be branched or cyclic;
    or wherein R¹ and R² together represent -(CH₂) n -, wherein n is 3, 4, 5.
    and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.

    摘要翻译: 具有式CHEM的化合物,其中R 1是可以是支链或环状的C 1-6 - 烷基; R 2是可以是支链或环状的C 1-6 - 烷基; 或其中R 1和R 2一起表示 - (CH 2)n - ,其中n为3,4,5。一种治疗哺乳动物(包括人)的障碍的方法,其对谷氨酸的阻断和 天冬氨酸受体,同样。

    Isatine derivatives, their preparation and use
    7.
    发明公开
    Isatine derivatives, their preparation and use 失效
    ISATINE衍生物,其制备和使用

    公开(公告)号:EP0432648A3

    公开(公告)日:1991-09-25

    申请号:EP90123474.0

    申请日:1990-12-06

    申请人: NEUROSEARCH A/S

    IPC分类号: C07D209/40 A61K31/40

    CPC分类号: C07D209/40

    摘要: A method of treatment with compounds having the formula

    wherein
    R¹ is hydrogen, C₁₋₆-alkyl which may be branched, C₃₋₇-cycloalkyl, benzyl, phenyl which may be substituted, acyl, hydroxy, C₁₋₆-alkoxy, CH₂CO₂R' wherein R' is hydrogen or C₁₋₆-alkyl which may be branched, CH₂CN, CH₂CONR IV R V wherein R IV and R V independently are hydrogen or C₁₋₆-alkyl, or CH₂C(=NOH)NH₂;
    R² is hydrogen, benzyl, C₁₋₆-alkyl which may be branched, or C₃₋₇-cycloalkyl;
    R⁴, R⁵, R⁶, R⁷ independently are hydrogen, C₁₋₆-alkyl which may be branched, phenyl, halogen, C₁₋₆-alkoxy, NO₂, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, or CF₃; or R⁶ and R⁷ together form an additional 4 to 7 membered ring which may be aromatic or partial saturated and which may be substituted with halogen, NO₂, CF₃, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, and R⁴ and R⁵ have the meanings set forth above, are disclosed, as well as pharmaceutical compositions thereof. Certain of the compounds are novel. The compounds and pharmaceutical compositions containing the compounds are useful in the treatment of central nervous system disorders and especially conditions sensitive to excitatory amino acids.